Although the development and practical use of radiopharmaceuticals mediated by prostate-specific membrane antigen (PSMA) for the diagnosis and endoradiotherapy of prostate cancer have recently shown good results, further development continues in a search of new and more efficient targeting agents capable of enhancing the effect of treatment. Here, FOLH1 is linked to prostate carcinoma.